Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

A pharma giant expresses interest in a Stamford biotech company after striking a deal worth up to $1.3 billion for a New ...

The president has said the law is unfair to U.S. businesses. But lawyers say weakening it could end up costing corporate ...

In a phase 2 study, the company's medication suzetrigine barely performed better than a placebo in treating painful ...

U.S. Senator Tammy Baldwin (D-WI) joined a group of her colleagues in introducing the Capping Prescription Costs Act, ...

Glenmark reported a consolidated net profit of 3.48 billion rupees (USD 40.15 million) for the quarter ended December 31.

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has attracted significant investment activity from Venrock Healthcare Capital ...

A trade expert claims that Trump’s current tariff plan “reflects a fundamental misunderstanding of how the global economy ...

The auto threat offers to put some of the biggest brands in Japan, Germany and South Korea in Trump’s crosshairs.

City brokers expect dividends on GSK shares will keep marching higher. Is the FTSE 100 share a top passive income stock to ...

Equities research analysts at William Blair reduced their Q3 2025 earnings per share estimates for shares of AptarGroup in a ...